TY - JOUR AB - Global gene expression profiling identifies predictive and prognostic biomarkers and rationalizes breast cancer subtype-targeted treatment. The Anthracyclin/Taxol and survival pathway specific small molecular inhibitors, constitute current treatment options. These options are associated with acquired tumor resistance and emergence of drug-resistant cancer stem cells. Dietary supplements and constitutive bioactive phytochemicals with relatively low systemic toxicity may provide testable alternatives for current therapy. Human breast epithelial cell lines 184‑B5 (non‑tumorigenic triple negative cell type) and MDA‑MB‑231 (breast carcinoma derived triple negative cell type) were used as the experimental models. Putative cancer chemo‑preventive natural products and their constitutive bioactive agents represented the test agents. Anchorage independent growth, cell cycle progression and cell apoptosis quantified the treatment efficacy. Compared to the 184‑B5 cells, the MDA‑MB‑231 cells exhibited anchorage-independent growth indicative of persistent cancer risk. Additionally, the MDA‑MB‑231 cells exhibited hyper‑proliferation, accelerated cell cycle progression and inhibited apoptosis indicative of loss of homeostatic growth control. The test agents inhibited anchorage-independent growth via cytostatic and pro‑apoptotic effects. The triple negative carcinoma-derived Doxorubicin-resistant phenotype exhibited cancer stem cell markers, including tumor spheroid formation and expression of CD44, NANOG and c‑Myc. These data identify clinically relevant mechanistic leads for the efficacy of natural products in the aggressive therapy‑resistant breast cancer subtype and suggests a testable approach for cancer stem cell-targeted therapy. AD - Cancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645‑1559, USA AU - Telang,Nitin DA - 2017/09/01 DO - 10.3892/br.2017.958 EP - 204 IS - 3 JO - Biomed Rep KW - natural product clinical breast cancer PY - 2017 SN - 2049-9434 2049-9442 SP - 199 ST - Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer (Review) T2 - Biomedical Reports TI - Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer (Review) UR - https://doi.org/10.3892/br.2017.958 VL - 7 ER -